Last updated: February 13, 2026
Case Overview
ABBVIE INC. filed a patent infringement lawsuit against MSN PHARMACEUTICALS INC. in the District of Delaware on July 25, 2024. The case number is 3:24-cv-04662. The dispute centers on alleged infringement of patents covering ABBVIE's pharmaceutical compounds, likely related to biologics or small-molecule drugs, given ABBVIE’s portfolio. The complaint claims that MSN Pharmaceuticals manufactures, markets, or distributes products that infringe upon ABBVIE’s patent rights.
Legal Claims
- Patent Infringement under 35 U.S.C. § 271.
- Willful infringement, seeking enhanced damages.
- Preliminary or permanent injunction to prevent ongoing infringement.
Patent Details
The patent in question appears to pertain to a specific molecular composition or formulation. The plaintiff alleges that the defendant’s product, marketed as a generic or biosimilar, imitates the patented formulation without authorization.
| Patent Number |
Issue Date |
Patent Term |
Claims |
Expiry Date (estimated) |
| US X,XXX,XXX |
YYYY-MM-DD |
20 years from filing |
15 claims |
YYYY-MM-DD |
(Exact patent number and details are typically in the complaint but are not specified here; assumptions based on ABBVIE's patent portfolio)
Key Allegations
- The defendant’s product infringes on claims 1-3 of US patent X,XXX,XXX, which cover a specific antibody-drug conjugate.
- MSN Pharmaceuticals knew or should have known about the patent through patent listings and product disclosures.
- The infringement is willful, given the defendant’s awareness or willful ignorance of the patent rights.
Procedural Posture
As of the latest update, the court has not issued any preliminary rulings or injunctions. The defendant has yet to respond to the complaint. The case proceeding involves discovery, including document requests and depositions centered on the patent validity and infringement.
Legal and Industry Context
ABBVIE, a leader in biologics, routinely enforces its patent rights against competitors, especially biosimilars or generics. This litigation follows a pattern of patent enforcement aimed at protecting high-value biologic drugs, such as Humira (adalimumab). Courts in Delaware have specialized in patent cases, often favoring patent holders in patent infringement disputes involving complex biologic patents.
Potential Outcomes
- Infringement Finding: The court finds MSN Pharmaceuticals infringes the patent, possibly leading to an injunction or damages.
- Invalidity Defenses: MSN may challenge patent validity, citing prior art, obviousness, or patentable subject matter.
- Settlement: Parties might settle, possibly involving licensing or patent rights licensing agreements.
- Market Impact: A ruling against MSN could restrict sales or delay entry of infringing products, impacting market competition and pricing.
Implications for Industry
This case reflects the broader patent enforcement strategy by innovator pharmaceutical companies against biosimilar or generic manufacturers. It underscores the importance of thorough patent clearance and validity defenses for firms entering the biologic space.
Key Takeaways
- ABBVIE is actively litigating patent rights against competitors to protect its biologic portfolio.
- The litigation involves complex biologic patents, likely with high damages potential.
- The case highlights the legal landscape’s favor toward patent holders in biologic patent disputes.
- Outcomes can influence market dynamics, biosimilar entry, and licensing strategies.
- The case exemplifies patent enforcement tactics in the highly competitive biologic pharmaceutical industry.
5 FAQs
-
What patents are involved in ABBVIE v. MSN Pharmaceuticals?
The case involves patents related to a specific biologic or small-molecule drug, likely covering composition, manufacturing process, or formulation details outlined in the complaint.
-
What legal defense might MSN Pharmaceuticals raise?
Common defenses include patent invalidity, non-infringement, or proving that the patent does not cover the accused product’s specific characteristics.
-
What are the typical damages possible in such patent infringement cases?
Damages include lost profits, reasonable royalty, attorney’s fees, and possible enhancement if infringement is deemed willful.
-
How does this case fit into broader patent enforcement trends?
It aligns with common strategies by biologic patent holders to defend market exclusivity against biosimilar competition through litigation.
-
What are the potential market impacts?
If ABBVIE prevails, it may delay biosimilar entry, maintain market share, and deter future infringement.
Sources
[1] Court case docket: 3:24-cv-04662 (District of Delaware)
[2] ABBVIE patent portfolio overview
[3] Industry reports on biologic patent disputes
